FINWIRES · TerminalLIVE
FINWIRES

ASX:LDX

9 stories mentioning ASX:LDXUpdated just now

Every FINWIRES story that references ASX:LDX, newest first.

Asia

Lumos Diagnostics Receives Initial Blood Test Purchase Order Under Distribution Agreement; Shares Up 7%

Lumos Diagnostics Holdings (ASX:LDX) received an initial $767,800 purchase order from Phase Scientific for its FebriDx blood test, satisfying part of the year one minimum order quantity commitment under a distribution agreement with Phase Scientific, according to a Tuesday Australian bourse filing.The order is associated with the $5 million prepayment milestone received by Lumos following the grant of the CLIA waiver for FebriDx by the US Food and Drug Administration on March 27.Product delivery is expected to be fulfilled progressively between Tuesday and October.The company's shares climbed nearly 7% in recent trading on Tuesday.

ASX:LDX
Asia

Lumos Diagnostics Signs Exclusive Romania Distribution Agreement for Rapid Respiratory Infection Test; Shares Up 10%

Lumos Diagnostics Holdings (ASX:LDX) has entered into an exclusive distribution agreement with Romania-based Alpha Medical to commercialize its FebriDx rapid point-of-care diagnostic test across Romania, according to a Thursday filing with the Australian bourse.Alpha Medical has already placed an initial stocking order to ensure the products are available for immediate supply, per the filing.The partnership expands the company's European distribution network, building on agreements with Henry Schein and Interlux to broaden access to FebriDx through experienced regional partners, the filing added.The company's shares rose around 10% in recent Thursday trade.

ASX:LDX
Asia

Lumos Diagnostics Advances US Commercialization for Rapid Test; Shares Down 3%

Lumos Diagnostics (ASX:LDX) is advancing the commercialization strategy for its FebriDx rapid point-of-care test across its priority top 100 target list in the US, according to a Tuesday filing with the Australian bourse.The company is using a four-stage commercial framework to help track and communicate the progress of accounts, the filing said.FebriDx sales in the US are made through the company's exclusive distribution agreement with Phase Scientific, per the filing.Shares fell 3% in midday trade Tuesday.

ASX:LDX
Asia

Lumos Diagnostics Closes AU$5 Million Loan Facility With Two Shareholders

Lumos Diagnostics Holdings (ASX:LDX) said it closed down a AU$5 million secured loan facility with shareholders Tenmile Ventures and Ryder Capital Management, according to a Thursday filing with the Australian bourse.Lumos previously drew AU$1 million under the facility, which was established in September 2025, and repaid the outstanding balance in full following the completion and receipt of AU$20 million of placement proceeds in April.The company said it currently has no debt.Its shares gained 2% in recent Thursday trade.

ASX:LDX
Asia

Lumos Diagnostics Progresses Additional Pilot Sites With Urgent Care Operators For Respiratory Infection Testing Tool, Shares Jump 4%

Lumos Diagnostics Holdings (ASX:LDX) progressed numerous additional pilot sites with new urgent care operators/chains for its FebriDx rapid point-of-care test for acute respiratory infections, according to a Monday Australian bourse filing.The eight urgent care chains run by new operator ownership groups are progressing favourably in their evaluation and implementation of FebriDx, it added.Lumos is also receiving regular reimbursement updates through its consultants, PRO-spectus and AcuityMD, and is beginning to see early data from sites using FebriDx, which suggests that over 90% of submitted claims are being reimbursed.Its shares rose 4% in recent trading on Monday.

ASX:LDX
Asia

Lumos Diagnostics Hits Enrollment Milestone in Pediatric Clinical Study of Respiratory Infection Testing Tool; Shares Down 4%

Lumos Diagnostics Holdings (ASX:LDX) completed the enrollment of 250 patients in the Biomedical Advanced Research and Development Authority (BARDA)-funded pediatric clinical study of the FebriDx rapid point-of-care test for acute respiratory infections, according to a Thursday Australian bourse filling.This triggered a $670,000 milestone payment under Lumos' agreement with BARDA, bringing the total milestone payments received to date to $2.6 million, the filing said.The study is evaluating the use of the FebriDx device in children between the ages of two to 12 years to differentiate bacterial from non-bacterial acute respiratory infections, per the filing. It is expected to run for around 12 months.Lumos Diagnostics Holdings' shares tumbled 4% in recent Thursday trade.

ASX:LDX
Asia

Lumos Diagnostics Holdings Receives Milestone Payment for Achieving CLIA Waiver

Lumos Diagnostics Holdings (ASX:LDX) received a milestone payment of $507,377, under its contract with the Biomedical Advanced Research and Development Authority (BARDA) for achieving US Food and Drug Administration (FDA) CLIA waiver for its FebriDx rapid point-of-care test, according to a Thursday Australian bourse filing.The receipt of the payment from BARDA brings the total amount received under the CLIA waiver study to almost $3 million.

ASX:LDX
Asia

Lumos Diagnostics Expands FebriDx Test Rollout at WellStreet Urgent Care

Lumos Diagnostics Holdings (ASX:LDX) has expanded an agreement with WellStreet Urgent Care to roll out its FebriDx rapid point-of-care test to an additional 43 locations from a single initial site, according to a Tuesday filing with the Australian bourse.The expanded rollout will take place over the next two months, and once it is completed, Lumos expects WellStreet to launch FebriDx at all of the remaining outlets in its network of 163 urgent care locations, per the filing.The increased volume and enhanced payor visibility from the expanded rollout should also strengthen the company's position in future contract negotiations with other health care providers, Lumos said.

ASX:LDX
Asia

Lumos Diagnostics Receives $5 Million Prepayment From US Distribution Partner, Shares Up 3%

Lumos Diagnostics (ASX:LDX) has received a $5 million prepayment for product from US distribution partner PHASE Scientific, confirming that the US Food and Drug Administration's 510(k) clearance with CLIA waiver for FebriDx product satisfies the milestone requirements of the PHASE distribution agreement, according to a Tuesday Australian bourse filing.The company said the $5 million represents a prepayment for future sales and will be recorded as revenue when the product is shipped, the filing added.The company's shares rose 3% in recent Tuesday trade.

ASX:LDX

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:LDX in your portfolio
WheelAI
WheelAI
Analyze ASX:LDX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:LDX